Hematologic Malignancies Market Size To Hit US$ 151.31 Billion By 2032, Fueled By Rising Blood Cancer Burden And Precision Medicine Integration S&S Insider

(MENAFN- GlobeNewsWire - Nasdaq) Advancements in Oncology Propel Hematologic Malignancies Market: Latest Innovations Drive Significant Growth and Transform Blood Cancer Care

Austin, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Hematologic Malignancies Market Size Analysis:

According to S&S Insider Research, the Hematologic Malignancies Market is projected to grow at 9.11% annually over the next eight years, climbing from USD 75.47 billion in 2024 to USD 151.31 billion by 2032. The U.S. Hematologic Malignancies market was valued at USD 16.48 billion in 2024 and is projected to reach USD 32.60 billion by 2032, reflecting a CAGR of 8.93%.

Get Sample Report of Hematologic Malignancies Market @

Hematologic Malignancies: Expanding Cancer Diagnostics and Positioned to Advance Alongside Immunotherapies and Personalized Medicine

The Hematologic Malignancies (HM) market is rapidly growing owing to the increasing incidence of blood cancers around the world including leukemia, lymphoma, and multiple myeloma. Over 184,000 new cases were projected for the U.S. alone in 2023, according to the U.S. National Cancer Institute, forcing a need for novel treatments. As such, there has been a high demand for early diagnosis as well as novel therapeutics in the form of CAR-T therapies, targeted Biologics, and immunotherapies. They have been shown to be effective in prolonging survival and in improving quality of life, especially in cases of relapse or relapsed disease.

This expansion is driven by government initiatives and the quick-tracking of approvals. The FDA, EMA, and other agencies are expediting the regulatory process for hematologic oncology drugs, leading to faster access for patients to new therapies. In addition, awareness campaigns and cancer registries are increasing access to diagnostics, allowing patients to be diagnosed earlier. Collectively, these initiatives showcase the HM landscape finding solutions to some of the more significant unmet needs, ensuring that a greater share of patients receive timely, effective interventions.

Major Players Analysis Listed in this Report are:

• GlaxoSmithKline PLC
• Bristol-Myers Squibb Company
• Takeda Pharmaceutical Co. Ltd.
• Pfizer Inc.
• F. Hoffmann-La Roche Ltd.
• Johnson & Johnson
• Sanofi S.A.
• Novartis AG
• Amgen Inc.
• AbbVie Inc.
• Other Players

Hematologic malignancies are reported as 9.4% of all of the new cancers in the US, according to a study from the American Cancer Society in 2023. These cancers hinder oxygen transport, immunity, and clotting, and their increasing incidence highlights the need for more effective therapies. Regulators are creating a friendly environment for pharma by speeding drug approvals and increasing access to clinical trials. This provides wider access to therapies whilst limiting deaths from presentation and diagnosis at late-stage.

Classes of new therapies: checkpoint inhibitors, CAR-T cell treatments are changing the way we treat blood cancers. Research and development (R&D), accelerated by government funding and private investments, is increasingly equipping companies to deliver precision treatments and take precision medicine far beyond oncology07. Such advancements open up diverse opportunities for oncologist therapy individualization, leading to increased patient survival and continuous growth in the HM market globally.

Hematologic Malignancies (HM) Market Report Scope:

Report Attributes	Details
Market Size in 2024	USD 75.47 Billion
Market Size by 2032	USD 151.31 Billion
CAGR	CAGR of 9.11% From 2025 to 2032
Base Year	2024
Forecast Period	2025-2032
Historical Data	2021-2023
Regional Analysis	North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Key Growth Drivers	Rising global blood cancer incidence drives demand for diagnostics and treatments. Increasing adoption of CAR-T, immunotherapies, and biologics expands clinical options. Strong government initiatives and fast-track approvals improve treatment availability.

Segmentation Dynamics

By Disease , leukemia dominated the global market, accounting for 42% share due it high incidence and survival. Specific therapeutic strategies are necessary for subtypes like AML and CML, and this will also be made possible with continuous breakthroughs and donor registry-based funding. During the forecast period, lymphoma is anticipated to see the fastest growth due to 89,000 annual cases in the U.S. and greater utilization of immunotherapies. This is quite relevant as the approval of several CAR-T cell therapies during 2024 highlights the robust lymphoma-targeted pipeline.

By Therapy , hemotherapy reigned supreme with a 34% market share by Therapy, remaining a backbone therapy for blood cancer. Cytarabine and anthracyclines still play the role of workhorses, which is evidenced by FDA approvals of new indications. Immunotherapy, on the other hand, is expected to report the rapid growth, as it shows an increase in uptake of checkpoint inhibitors as well as CAR-T. Regulatory support and demand from patients are predicted to speed up immunotherapy uptake in all blood cancer subtypes.

By End Use , hospital pharmacies dominated the global hematologic cancer treatment market in 2024 with a revenue share of 56% owing to their pivotal role in the delivery of these complex therapies in hematologic cancer patients. As a result, these facilities bring together chemotherapy, immunotherapy, and supportive care, providing continuity for patients. The rapid uptake of oral therapies fuelling the forecast growth of retail pharmacies. Increased government reimbursement for outpatient-targeted drugs for leukemia and lymphoma is making it both easier for patients to get these drugs and be adherent to the medication regimes needed for the successful treatment of this cancer and its associated complications.

Need Any Customization Research on Hematologic Malignancies Market, Enquire Now:

Hematologic Malignancies (HM) Market Key Segmentation:

By Disease

• Leukemia
• Lymphoma
• Multiple Myeloma
• Others

By Therapy

• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Others

By End-User

• Hospital Pharmacies
• Retail Pharmacies
• Others

Regional Analysis

North America held the largest share of the hematologic malignancies market in 2024, attributed to its well-developed healthcare infrastructure and a high incidence of blood cancer. The U.S. represents an important share, with a market size of USD 16.48 billion in 2024, and expected to reach USD 32.60 billion by 2032 at a CAGR of 8.93% between 2024 and 2032. North America is at the forefront, buoyed by solid National Cancer Institute support, FDA fast-track approvals, and early uptake of new therapies.

Europe takes the No. 2 spot, with national cancer registries, established screening programs and generous reimbursement policies, and so on. Germany, the UK, and France are the top contributors, with approvals of new biologics and immunotherapies being a focus of the European Medicines Agency (EMA). Europe's regional leadership is built on a foundation of early detection and integrated cancer care.

The market in the Asia Pacific region is expected to observe rapid growth in the near future owing to rising cancer prevalence, increasing healthcare infrastructures, and government-supported cancer care programs. The expansion is caused by the large patient pools in China and India, as well as increasing investments in diagnostics and the development of CAR-T therapies. Japan is also an important market (with highly advanced oncology infrastructure and an ageing population) and remains, in our view, an important driver of demand.

Regions such as Latin America, the Middle East, and Africa (LAMEA) signify emerging territories with promising infrastructure and enhanced awareness. Oncology centers are being built and the access to essential medicines are being expanded through the investments from governments of Brazil, China, South Africa and the GCC countries. Short- to medium-term health market (HM) development is bolstered by increasing healthcare investments, although limited resources and financial disparities continue to create challenges.

Get the Full Report of Hematologic Malignancies Market Report (Single-User License):

Exclusive Sections of the Report (The USPs):

• PRESCRIPTION & TREATMENT TRENDS – helps you analyze regional differences in drug adoption, treatment preferences, and evolving therapeutic approaches shaping patient outcomes.
• PHARMACEUTICAL VOLUME & USAGE METRICS – helps you track demand patterns, drug utilization rates, and market share shifts among leading therapies in hematologic malignancies.
• DIAGNOSTIC & MONITORING INNOVATIONS – helps you understand the adoption of advanced testing and monitoring devices that drive early detection, personalized treatment, and improved patient management.
• CLINICAL TRIAL & PIPELINE LANDSCAPE – helps you evaluate ongoing R&D activity, late-stage trial outcomes, and the innovation pipeline fueling the next wave of targeted and immuno-oncology therapies.
• COMPETITIVE LANDSCAPE – helps you gauge the positioning of leading pharmaceutical and biotech players based on product portfolios, market reach, trial activity, and growth strategies.

Access Complete Report Details of Hematologic Malignancies Market Analysis & Outlook@

[For more information or need any customization research mail us at ...]

About Us:

S&S Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: ...

MENAFN18092025004107003653ID1110080028